Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Details
Odpornost proti antibiotikom pri probiotičnih bakterijah
ID
Stražišar, Neža
(
Author
),
ID
Bogovič Matijašić, Bojana
(
Mentor
)
More about this mentor...
PDF - Presentation file,
Download
(1,24 MB)
MD5: 4FF15D810C7CE591DCE2C4D8F624A55D
Image galllery
Abstract
Številne študije so potrdile ugoden vpliv uporabe probiotikov na gostitelja, tako pri ljudeh kot pri živalih. Uporaba probiotikov po vsem svetu narašča. V zadnjem času pa so znanstveniki začeli opozarjati na to, da tudi ti namerno zaužiti mikroorganizmi lahko predstavljajo potencialni vir genov za odpornost proti antibiotikom, ki se lahko prenašajo med bakterijami različnih vrst. Evropska agencija za varnost hrane EFSA (angl. European Food Safety Authority) v okviru koncepta QPS (angl. Qualified Presumption of Safety) skrbi, da se v živilih in prehranskih dopolnilih uporabljajo le tiste vrste bakterij, ki so varne, poleg tega pa je med kriteriji varnosti omenjena tudi odsotnost prenosljivih genov za odpornost proti antibiotikom. To je mogoče zagotoviti le z ugotavljanjem prisotnosti z odpornostjo proti antibiotikom povezanih genov v celotnih genomih posameznih sevov. Danes je postalo dostopno ugotavljanje nukleotidnega zaporedja celotnih bakterijskih genomov, v preteklosti pa so se posluževali zgolj fenotipskega testiranja. Razen intrinzične oziroma naravne odpornosti so pri mnogih sevih bakterij iz rodov Lactobacillus in Bifidobacterium, iz katerih izhajajo tudi številni probiotiki, odkrili tudi pridobljene gene za odpornost, med katerimi prednjačijo tisti za odpornost proti eritromicinu, tetraciklinom in aminoglikozidom. Prenos nekaterih takih genov, na primer prenos gena za odpornost proti vankomicinu, med enterokoki in laktobacili, so opazili tudi in vitro in in vivo v miših. Prenosa genov za odpornost proti antibiotikov iz mlečnokislinskih bakterij ali bifidobakterij v patogene in vivo še niso dokazali, potencialne nevarnosti pa ne moremo izključiti. Zato je zelo pomembna redna kontrola probiotičnih bakterij v izdelkih na trgu, ki zajema tudi ugotavljanje fenotipske in genotipske odpornosti proti antibiotikom.
Language:
Slovenian
Keywords:
biotehnologija
,
probiotiki
,
prenos odpornosti
,
odpornost proti antibiotikom
Work type:
Bachelor thesis/paper
Typology:
2.11 - Undergraduate Thesis
Organization:
BF - Biotechnical Faculty
Publisher:
[N. Stražišar]
Year:
2018
PID:
20.500.12556/RUL-103955
UDC:
577.181:615.015.8(043.2)
COBISS.SI-ID:
9060217
Publication date in RUL:
29.09.2018
Views:
4581
Downloads:
438
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
STRAŽIŠAR, Neža, 2018,
Odpornost proti antibiotikom pri probiotičnih bakterijah
[online]. Bachelor’s thesis. N. Stražišar. [Accessed 30 April 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=103955
Copy citation
Share:
Secondary language
Language:
English
Title:
Antibiotic resistance among probiotic bacteria
Abstract:
A number of studies have confirmed the beneficial effect of the use of probiotics on the host, both in humans and in animals. The use of probiotics worldwide is rising. Lately, scientists have begun to warn that even deliberately ingested microorganisms can present a potential source of antibiotic resistance genes that can be transmitted among bacteria of various species. The European Food Safety Authority (EFSA), within the framework of the Qualified Presumption of Safety (QPS) concept, ensures that only those species of bacteria that are safe are used in foods and dietary supplements, and beside this, also the absence of transferable antibiotic resistance genes is mentioned. This can be assured only by determination of the presence of the genes associated with antibiotic resistance in the entire genomes of individual strains. Nowadays, the detection of the nucleotide sequences of total bacterial genomes has become available, and in the past phenotypic testing was only performed. Apart from intrinsic or natural resistance, the acquired resistance genes were found in many strains of bacteria from Lactobacillus and Bifidobacterium genera, among which those for erythromycin, tetracycline and aminoglycoside resistances predominate. The transfer of some antibiotic resistance genes, for example the transfer of the vancomycin resistance gene between enterococci and lactobacilli, have also been observed in vitro and in vivo in mice. The transmission of antibiotic resistance genes from lactic acid bacteria or bifidobacteria to pathogens in vivo has not been demonstrated yet, and potential risks can not be ruled out. For this reason regular control of probiotic bacteria on the market is very important, which also includes the identification of phenotypic and genotypic resistance to antibiotics.
Keywords:
biotechnology
,
probiotics
,
transfer
,
antibiotic resistance
Similar documents
Similar works from RUL:
ǂThe ǂimportance of cancer stem cells and epithelial-mesenchymal transition in the progression of non-small cell lung cancer
Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
Study of phosphatidylethanolamine N-methyltransferase gene expression in non-small cell lung cancer tissue
Usefulness of immunohistochemically determined epidermal growth factor receptor mutations in lung cancer
Diabetes mellitus and physical activity
Similar works from other Slovenian collections:
Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
Outsourcing predictive biomarker testing in non-small cell carcinoma
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
NSCLC molecular testing in Central and Eastern European countries
Back